Real World Study of TrEatment Discontinuations and Modifications for Patients With HER2+ and HER2-low Metastatic Breast Cancer On Trastuzumab Deruxtecan

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 11 Mar 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Trastuzumab-deruxtecan (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms HER-TEMPO
Sponsors AstraZeneca

07 Mar 2025 Planned End Date changed from 4 Apr 2025 to 8 Dec 2025.
07 Mar 2025 Planned primary completion date changed from 4 Apr 2025 to 8 Dec 2025.
07 Mar 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com